On Dec. 19, the Food and Drug Administration (FDA) approved Rubraca (rucaparib) to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have the gene mutation deleterious BRCA as identified by an FDA-approved companion diagnostic test. Read more.
FDA approves new treatment for advanced ovarian cancer
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.